Yongfen Ma

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 3

Top Topics

Placebo Controlled

Top Venues

Clinical and translational science

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ana Liza Andresan Sun, John David Gillies, Yang Shen, Huajun Deng, Fenchao Xue, Yongfen Ma, Linan Song
A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants. Clinical and translational science 17 (7) (2024)
Ana Liza Andresan Sun, John David Gillies, Yang Shen, Huajun Deng, Fenchao Xue, Yongfen Ma, Linan Song
A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants. Clinical and translational science 17 (7) (2024)
Shiming Peng, Wen Xiao, Dapeng Ju, Baofa Sun, Nannan Hou, Qianlan Liu, Yanli Wang, Haijiao Zhao, Chunchun Gao, Song Zhang, Ran Cao, Pengfei Li, Huanwei Huang, Yongfen Ma, Yankai Wang, Weiyi Lai, Zhixiong Ma, Wei Zhang, Song Huang, Hailin Wang, Zhiyuan Zhang, Liping Zhao, Tao Cai, Yong-Liang Zhao, Fengchao Wang, Yongzhan Nie, Gang Zhi, Yun-Gui Yang, Eric Erquan Zhang, Niu Huang
Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1. Science translational medicine 11 (488) (2020)